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Bluetongue has emerged recently in Belgium. A blue-
tongue virus strain was isolated and characterized as
serotype 8. Two new real-time reverse transcription–quan-
titative PCRs (RT-qPCRs) that amplified 2 different seg-
ments of bluetongue virus detected this exotic strain. These
2 RT-qPCRs detected infection earlier than a competitive
ELISA for antibody detection.
B
luetongue is a noncontagious disease caused by an
orbivirus of the family Reoviridae. The bluetongue
virus (BTV) serogroup consists of 24 serotypes. BTV is
transmitted by arthropods of the genus Culicoides and its
distribution worldwide is restricted to regions that contain
competent vectors (1). An outbreak of bluetongue was
reported and confirmed in the Netherlands on August 17,
2006 (2). Belgium reported its first cases of bluetongue 1
day later, and Germany and France reported outbreaks on
August 21, 2006, and August 31, 2006, respectively (2,3).
We report detection and characterization of a BTV strain
and an overview of laboratory test results 4 weeks after the
onset of the outbreak.
The Study
Twenty-one animals (16 cattle and 5 sheep) showing
clinical signs suggestive of bluetongue were sampled by
the Federal Agency for the Safety of the Food Chain on
August 18, 2006, at 11 farms in northeastern Belgium.
Two serologic tests that detect antibodies against the major
serogroup antigen VP7 (bluetongue virus antibody com-
petitive ELISA [cELISA]; Veterinary Medical Research
and Development Inc., Pullman, WA, USA and competi-
tive vp7 bluetongue kit; IDVET, Montpellier, France)
identified 21 virus-positive animals. Two newly developed
and validated reverse transcription–quantitative PCRs (RT-
qPCRs) that detected BTV strains representing the 24
serotypes (4) were then conducted to determine whether
these seropositive animals also had viral RNA. The first
assay (RT-qPCR_S1), which amplified a 357-nt fragment
in segment 1, detected virus in erythrocytes of the 21
seropositive animals (mean cycle threshold [Ct] value
29.0). The second assay (RT-qPCR_S5), which amplified a
94-nt fragment in segment 5, detected virus in the same 21
seropositive animals (mean Ct value 26.5). The 2 serolog-
ic tests and the 2 molecular assays detected BTV in 21 ani-
mals from 11 Belgian farms within 14 hours.
Virus isolation was conducted on August 18, 2006, by
injection of blood from infected sheep into 11-day-old
embryonated chicken eggs, followed by passage on BHK-
21 cells (ATCC-CCL10) as previously described (5). The
specificity of the cytopathic effect observed 48 hours after
passage on BHK-21 cells was confirmed by RT-qPCR and
electron microscopy (Figure 1) after fixation and negative
staining as previously described (6). Two virus neutraliza-
tion tests were conducted on 2 virus strains isolated by the
Belgian and the French reference laboratories at 2 Belgian
farms 30 km apart. The 2 BTV isolates were completely
neutralized with reference serum for serotype 8. Each
strain was also partially neutralized by reference serum
against serotype 18, which confirmed cross-neutralization
between serotypes 8 and 18 (7).
From August 19, 2006, to September 14, 2006, the
study farms were screened for animals with clinical signs
of bluetongue. Blood samples were tested by serologic
tests or RT-qPCR. For cattle, 97 (68%) of 142 samples had
antibodies to BTV and 32 (78%) of 41 samples contained
viral RNA(Table 1). However, for sheep, only 23 (29%) of
79 samples had antibodies to BTV and 15 (45%) of 33
samples contained viral RNA. Other diseases that cause
similar signs might explain this lower frequency in sheep.
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Figure 1. Negatively stained bluetongue virus–like particle that
caused a cytopathic effect in BHK-21 cells. Scale bar = 50 nm. Contagious ecthyma was diagnosed by using PCR and
electron microscopy for several sheep that showed blue-
tonguelike signs but did not have antibodies to BTV or
viral RNA.
Agreement between cELISA and RT-qPCR results
was analyzed for 124 animals (Table 2). One sample neg-
ative by RT-qPCR_S1 and RT-qPCR_S5 was positive by
cELISA. Although this result might reflect lack of speci-
ficity of the cELISA, elimination of BTV RNA from the
animal several weeks after being infected cannot be ruled
out. A false-negative result in the RT-qPCR is unlikely
because 1) 2 different RT-qPCRs that amplified 2 different
segments were used, 2) the quality of the RNA was con-
firmed by a third RT-qPCR that quantified mRNA of
β-actin, and 3) both RT-qPCRs are highly sensitive (they
can detect 0.01 infectious doses of virus) (4). False-posi-
tive results were not observed with the IDVET cELISA
when we analyzed 650 negative serum samples from arti-
ficial insemination centers and field samples collected
from  Belgian livestock in 2004 and 2005. Thus, the speci-
ficity of the cELISA is >99.8%. Seven animals with blue-
tonguelike clinical signs were positive according to each
RT-qPCR but negative according to the cELISA (Table 2).
These results support the finding that RT-qPCR can be
used to detect viral RNA in infected animals before anti-
bodies are detectable. The clinical signs indicative of a
recent infection support this finding.
On September 14, 2006 (4 weeks after the first identi-
fication of BTV in Belgium) as many as 84 Belgian farms
had at least 1 BTV-infected animal. The maximal distance
between herds in this study was ≈110 km (Figure 2A).
Most outbreaks were confirmed in the area where the dis-
ease was initially detected (area I, Figure 2). Most (64%)
infected animals showed a high virus load with individual
Ct values <30. Of the remaining animals, 30% had moder-
ate virus loads (Ct values 30–35) and 6% had Ct values
>35. The high Ct values for the latter animals might have
remained undetected had pooled blood samples been ana-
lyzed. Thus, results of pooled samples need to be validat-
ed before being used for diagnosis. Distribution of Ct
values differed slightly, depending on the origin of the ani-
mals. None of the animals from zones III and IV showed a
Ct value <30, whereas all animals from zone II showed
low Ct values, which are indicative of high virus loads.
Lower virus loads and acute clinical signs in animals from
zones III and IV might indicate onset of infection.
However, we cannot rule out decreased infection in these
animals because they also had positive serologic results
that indicated infection for at least 4–5 days. Further epi-
demiologic studies are required before conclusions can be
drawn on the evolution of these epidemics.
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Figure 2. A) Distribution of outbreaks of bluetongue (shaded
areas) reported in Belgium from August 18 through September 14,
2006. Area I is where the disease was initially detected. B) Cycle
threshold (Ct) values observed in different zones as a result of
conducting reverse transcription–quantitative PCR_S5 on individ-
ual blood samples.
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Conclusions
Bluetongue has emerged in some countries of north-
ern Europe. BTV has been detected and its isolation and
characterization have considerably progressed in the first
weeks of the epidemics. Results of virus neutralization
tests for 2 Belgian isolates and molecular characterization
of the Dutch BTV strain by the community reference lab-
oratory (8) indicate that BTV serotype 8 is present in
Belgium and the Netherlands. Although this observation
suggests 1 serotype circulating in northern Europe after a
common virus introduction, it must be confirmed by
detailed epidemiologic studies. The mechanism of intro-
duction of BTV strain serotype 8 is unknown. Northward
spread of bluetongue in Europe has been correlated with
climate warming (9). However, BTV serotype 8 has not
been found in the Mediterranean basin.
One characteristic of the current epidemics of blue-
tongue is the severity of clinical signs reported in cattle
(10). The present results also demonstrate that clinical
signs observed in cattle are more specific than those
observed in sheep. Confusing clinical signs in sheep
underline the need for developing diagnostic tests to dis-
criminate between bluetongue and other confounding dis-
eases such as contagious ecthyma, border disease, and
foot-and-mouth disease. Our results also indicate the use-
fulness of RT-qPCR, which detected viral RNAin recently
infected animals with clinical signs of bluetongue but no
detectable antibodies to BTV. The RT-qPCR and ELISA
are independent but complementary tests because they
detect viral RNAand virus-specific antibodies, respective-
ly. These tests indicated that an outbreak of bluetongue
was occurring in Belgium. Despite high sensitivity of RT-
qPCR (4), our results suggest that using this test with
pooled samples might not detect animals with low viral
loads. This possibility should be explored and validated by
testing individual and pooled samples. RT-PCR–positive
results in animals that are no longer infectious (11) should
also be considered before deciding whether pooled sam-
ples are acceptable.
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